Comparison

Mounjaro vs Compounded Tirzepatide

Both deliver tirzepatide — the dual GIP/GLP-1 receptor agonist — but via different regulatory pathways. Mounjaro is the ARTG-registered Eli Lilly product; compounded tirzepatide is dispensed under TGA SAS-B by a licensed Australian compounding pharmacy.

Mounjaro vs Compounded tirzepatide — head to head

AttributeMounjaroCompounded tirzepatide
Active ingredientTirzepatideTirzepatide
Regulatory pathwayARTG-registered, standard private scriptTGA SAS-B / Authorised Prescriber
Where dispensedAny Australian pharmacyTGA-licensed compounding pharmacy
Delivery formatSingle-use pre-filled penMulti-dose vial + syringes
AUD cost / month~$400–$650 privatePer-case; often $300–$550 depending on dose
Dose flexibilityFixed pen strengthsPrescriber-set, vial concentration variable

Verdict

Mounjaro is the default when supply allows — standardised dose, ARTG-registered, dispensed at any Australian pharmacy. Compounded tirzepatide is a per-case clinical decision when there is documented clinical need or supply constraint.

Frequently asked questions

Is compounded tirzepatide legal in Australia?
Yes — when prescribed by an AHPRA-registered Australian doctor under TGA SAS-B and dispensed by a TGA-licensed Australian compounding pharmacy. It is not legal to import yourself or buy from offshore vendors.
Can I switch from compounded tirzepatide to Mounjaro?
Yes, with your prescriber's review — dose-match against your current titration and confirm pen strength availability. Most Australian prescribers will use Mounjaro as the default when supply is available.

Read the full profiles

Other comparisons

Be assessed by an Australian doctor

Take the free 5-minute intake. An AHPRA-registered Australian doctor will review your case and discuss the right molecule and pathway for you.

Start free assessment All peptides
Start free 5-min assessment